Drug Profile
Research programme: autologous fibroblast cell therapy - Fibrocell Science
Latest Information Update: 19 Dec 2019
Price :
$50
*
At a glance
- Originator Fibrocell Science
- Developer Fibrocell Science; Uniformed Services University of the Health Sciences
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 16 Dec 2019 Fibrocell Science has been acquired by Castle Creek Pharmaceuticals
- 28 Dec 2018 No recent reports of development identified for preclinical development in Skin-disorders(Prevention) in USA (Parenteral)
- 18 Nov 2014 The US FDA approves IND application for autologous fibroblast cell therapy in Skin disorders